Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 08, 2023, titled "Zydus receives final approval from the USFDA for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg".
Press Release Jun 08 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Esomeprazole Magnesium for Delayed-Release Oral Suspension in two dosages. This medication is used to treat stomach and esophagus problems by reducing stomach acid production. The product will be manufactured at Zydus's facility in Moraiya, Ahmedabad. The press release highlights that the product had significant annual sales in the United States.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jun 07 2023
- Press Release May 18 2023
- Press Release May 17 2023
- Press Release May 10 2023
- Press Release May 04 2023
Later from Zydus Lifesciences
- Press Release Jun 09 2023
- Press Release Jun 10 2023
- Press Release Jun 13 2023
- Press Release Jun 19 2023
- Press Release Jun 28 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences